MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in KRAS -Mutated Non-Small Cell Lung Cancer.
Francesca FaniniErika BandiniMeropi PlousiouSilvia CarloniPetra WisePaolo NevianiMariam MurtadhaFlavia FocaFrancesco FabbriIvan VanniniMuller FabbriPublished in: International journal of molecular sciences (2021)
-activating mutations.